RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings

(2009) Sebastian Hoefert et al.   Clinical Oral Investigations

20LBA A double-blind, randomized study of denosumab versus zoledronic acid for the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma

(2009) D. Henry et al.   EJC SUPPLEMENTS

2LBA Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study

(2009) A. Stopeck et al.   EJC SUPPLEMENTS

Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous Bisphosphonates

(2009) Karim Fizazi et al.   JOURNAL OF CLINICAL ONCOLOGY

Longitudinal Cohort Study of Risk Factors in Cancer Patients of Bisphosphonate-Related Osteonecrosis of the Jaw

(2009) Konstantinos Vahtsevanos et al.   JOURNAL OF CLINICAL ONCOLOGY

Editorial Board

(2009)   JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY

Bisphosphonates in Oncology: Rising Stars or Fallen Heroes

(2009) T. Van den Wyngaert et al.   ONCOLOGIST

Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid

(2008) M. A. Dimopoulos et al.   ANNALS OF ONCOLOGY

Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome

(2008) T. Van den Wyngaert et al.   ANNALS OF ONCOLOGY

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan

(2008) C. I. Ripamonti et al.   ANNALS OF ONCOLOGY

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

(2008) Ana O Hoff et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw

(2008) Beatrice J Edwards et al.   LANCET ONCOLOGY

Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy

(2008) C. L. Estilo et al.   ONCOLOGIST